Navigation Links
Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
Date:9/10/2012

THOUSAND OAKS, Calif., Sept. 10, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of Ray Jordan to the new position of senior vice president, Corporate Affairs, effective October 1.

Jordan will report directly to Robert A. Bradway, president and chief executive officer, and will be responsible for strategic communications across Amgen, including internal and external communications, issues management and philanthropy.

Since 2003 Jordan has served as communications leader at Johnson & Johnson, responsible for corporate communications and public affairs for more than 250 operating companies in 60 countries.  Prior to joining Johnson & Johnson, Jordan was vice president, communications and information, for Pfizer, where he held a range of positions over the course of 17 years. He also served as chair of PhRMA's public affairs section and of the National Pharmaceutical Council's User Group. Earlier in his career, Jordan was a reporter for a regional daily newspaper and held positions with Bristol-Myers and Dun & Bradstreet.

"We are very pleased to have Ray join Amgen," said Bradway.  "He is a strategic thinker and communicator with skills honed at two respected global health care companies.  Ray's background in both business management and communication will serve Amgen well as we execute on our strategy to deliver results for both patients and shareholders."

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid art
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
11. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , Nov. 25, 2014  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne pathogens, ... at the Piper Jaffray  26 th Annual Healthcare Conference ... be held at The New York Palace in ... presentation, material information concerning the Company, its operations, strategies and ...
(Date:11/24/2014)... , UAE, November 24, 2014 ... Hamdan Bin Rashid Al Maktoum Awards for Medical Sciences", ... Dubai, United Arab Emirates , on 15 ... ) , The Carter Center which won ... is actively involved in numerous programs that aim to ...
(Date:11/24/2014)... Nov. 24, 2014 VolitionRx Limited (OTCQB: ... for cancer and other conditions, today announced that data from ... Science for Business BioWin Day 2014, being held November 26, ... come from VolitionRx,s lung cancer pilot study, the samples for ... Hospitalier Universitaire (CHU) de Liege in Belgium ...
(Date:11/24/2014)... 24, 2014   Veracyte, Inc. (Nasdaq: ... president and chief executive officer, will present in a fireside ... Healthcare Conference on Tuesday, December 2, 2014 at 12:30 p.m. ... The live audio webcast and subsequent replay may be accessed ... to the website at least 15 minutes prior to the ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2
... Dec. 6, 2010 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... 2010 Deutsche Bank BioFest on Tuesday, December 14, 2010. ...  The session may be accessed through the Company,s web ...  An archived version of the presentation will be available ...
... YM BioSciences Inc. (NYSE Amex: YMI ; TSX: ... patients enrolled in the Phase I/II trial for its JAK1/JAK2 ... an oral presentation at the 52nd American Society of Hematology ... "Anemia is the most serious symptom associated with myelofibrosis, so ...
... Md., Dec. 6, 2010 Viruses have a bad ... quickly and precisely replicate itself makes it a destructive ... team of researchers at the University of Maryland,s A. ... and Natural Resources, brought together by Professor Reza Ghodssi, ...
Cached Biology Technology:YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6Bad Virus Put to Good Use: Breakthrough Batteries 2Bad Virus Put to Good Use: Breakthrough Batteries 3Bad Virus Put to Good Use: Breakthrough Batteries 4Bad Virus Put to Good Use: Breakthrough Batteries 5Bad Virus Put to Good Use: Breakthrough Batteries 6
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... 20, 2014 C-Labs LLC, a leading provider ... Things (IoT), today announced the appointment of John ... Previously a strategic advisor to the firm, Mr. Traynor ... Traynor is based out of the C-Labs office in ... Chris Muench , Chief Executive Officer. ...
(Date:11/18/2014)... WASHINGTON , Nov. 18, 2014  The ... Security Industry Association today jointly announce the formation ... and release of its Identity and Biometric ... (Framework). The Framework received official support from BORDERPOL, ... governments to improve and provide expertise regarding border ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... study shows that land-use policies in Peru have been ... that country. Scientists at the Carnegie Institutions Department of ... years of high-resolution satellite data covering most (79%) of ... published in the August 9, 2007, on-line edition of ...
... New Haven, Conn. It is not just whats in your ... difference between species at least in yeast according to ... Weve known for a while that the protein coding genes ... senior author Michael Snyder , the Cullman Professor of ...
... Today, researchers report for the first time that genetic ... only from the motherare directly linked to metabolic markers ... the role of mitochondrial genome variation in the pathogenesis ... Research ( www.genome.org ). According to the ...
Cached Biology News:Rain forest protection works in Peru 2Evolution is driven by gene regulation 2Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes 2
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
... novel expression vectors, we in-troduced a new concept, ... at tran-scriptional level at the T7 phage promoter, ... amplifying the plasmid copy number, The main advantage ... retains practically all of the outstanding features of ...
... This CLS number is a new product ... number. If showing no availability yet, please ... or contact customer service for assistance. ... Comp Dim: surface area 21 cm 2 ...
Biology Products: